{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:33:12Z","timestamp":1792891992569,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007393.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000}}],"reference-count":97,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007393.pub4","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T16:41:05Z","timestamp":1484325665000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Topical capsaicin (high concentration) for chronic neuropathic pain in adults"],"prefix":"10.1002","volume":"2021","author":[{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[{"name":"Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew SC","family":"Rice","sequence":"additional","affiliation":[{"name":"Pain Research, Department of Surgery and Cancer, Faculty of Medicine; Imperial College London; London UK"},{"name":"Department of Pain Medicine; Chelsea and Westminster Hospital NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cole","sequence":"additional","affiliation":[{"name":"Oxford Pain Relief Unit; Churchill Hospital, Oxford University Hospitals NHS Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Tan","sequence":"additional","affiliation":[{"name":"NICE Centre for Guidelines; National Institute for Health and Care Excellence; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD007393.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","article-title":"NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study","volume":"7","author":"Backonja","year":"2008","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007393.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"e109144","DOI":"10.1371\/journal.pone.0109144","article-title":"A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Bischoff","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-6405-10-5","article-title":"NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials","volume":"10","author":"Brown","year":"2013","journal-title":"AIDS Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/QAI.0b013e31823e31f7","article-title":"A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy","volume":"589","author":"Clifford","year":"2012","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1526-4637.2010.01004.x","article-title":"A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia","volume":"12","author":"Irving","year":"2011","journal-title":"Pain Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-6405-10-5","article-title":"NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials","volume":"10","author":"Brown","year":"2013","journal-title":"AIDS Research and Therapy"},{"issue":"24","key":"10.1002\/14651858.CD007393.pub4-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1212\/01.wnl.0000314647.35825.9","article-title":"Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0008|cit8","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of QUTENZA\u00ae in subjects with painful diabetic peripheral neuropathy (clinical study results) www.astellasclinicalstudyresults.com\/hcp\/study.aspx?ID=76"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0009|cit9","unstructured":"Astellas Pharma Inc (Responsible party) A phase III, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of QUTENZA\u00ae in subjects with painful diabetic peripheral neuropathy clinicaltrials.gov\/ct2\/show\/NCT01533428 NCT01533428"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.09.008","article-title":"Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study","author":"Simpson","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2377-10-92","article-title":"Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia","volume":"10","author":"Webster","year":"2010","journal-title":"BMC Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007393.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jpain.2010.01.270","article-title":"A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia","volume":"11","author":"Webster","year":"2010","journal-title":"Journal of Pain"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1526-4637.2009.00793.x","article-title":"NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension","volume":"11","author":"Backonja","year":"2010","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0014|cit14","unstructured":"Vanhove T A multicenter randomized, double-blind, controlled study to evaluate safety, tolerability and preliminary efficacy of two capsaicin concentration variations of NGX-1998 (10% or 20% w\/w) in subjects with postherpetic neuralgia (PHN) clinicaltrials.gov\/ct2\/show\/NCT01228838 NCT01228838"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jpain.2012.01.300","article-title":"Efficacy and safety of NGX-1998, a novel topical liquid formulation of capsaicin, in patients with postherpetic neuralgia: results of a multi-center, placebo-controlled trial","volume":"13 (4 Suppl 1)","author":"Webster","year":"2012","journal-title":"Journal of Pain"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/bja\/aer260","article-title":"Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch","volume":"107","author":"Anand","year":"2011","journal-title":"British Journal of Anaesthetics"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10198-014-0659-4","article-title":"The economic impact of chronic pain: a nationwide population-based cost-of-illness study in Portugal","volume":"17","author":"Azevedo","year":"2016","journal-title":"European Journal of Health Economics"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(11)70281-2","article-title":"Chronic pain: genes, plasticity, and phenotypes","volume":"11","author":"Baron","year":"2012","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007393.pub4-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","article-title":"Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice","volume":"153","author":"Bouhassira","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40265-015-0520-9","article-title":"Capsaicin 8% patch: a review in peripheral neuropathic pain","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"issue":"7","key":"10.1002\/14651858.CD007393.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(12)70134-5","article-title":"The role of the immune system in the generation of neuropathic pain","volume":"11","author":"Calvo","year":"2012","journal-title":"Lancet Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD007393.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3959(97)00005-5","article-title":"The visual analogue pain intensity scale: what is moderate pain in millimetres?","volume":"72","author":"Collins","year":"1997","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD007393.pub4-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"issue":"9","key":"10.1002\/14651858.CD007393.pub4-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007393.pub4-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010958.pub2","article-title":"Topical lidocaine for neuropathic pain in adults","author":"Derry","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"issue":"6","key":"10.1002\/14651858.CD007393.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0885-3924(99)00093-7","article-title":"Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain","volume":"18","author":"Edwards","year":"1999","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0031|cit31","unstructured":"QUTENZATM versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, non-inferiority efficacy and tolerability study www.astellasclinicalstudyresults.com\/hcp\/study.aspx?ID=83"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0032|cit32","unstructured":"Qutenza 179mg cutaneous patch www.medicines.org.uk\/emc\/medicine\/23156\/SPC\/qutenza 179mg cutaneous patch\/"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0033|cit33","unstructured":"23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org\/epoc-specific-resources-review-authors (accessed 30 November 2016) 2015"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0034|cit34","unstructured":"US Department of Health and Human Services Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products www.fda.gov\/ohrms\/dockets\/98fr\/990236Gd.pdf"},{"issue":"7","key":"10.1002\/14651858.CD007393.pub4-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/j.1532-2149.2012.00282.x","article-title":"Neuropathic pain needs systematic classification","volume":"17","author":"Finnerup","year":"2013","journal-title":"European Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007393.pub4-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/acr.20235","article-title":"Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden","volume":"62","author":"G\u00fclfe","year":"2010","journal-title":"Arthritis Care and Research"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiological Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD007393.pub4-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2296-14-28","article-title":"An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Family Practice"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.19","article-title":"Individualized pharmacological treatment of neuropathic pain","volume":"97","author":"Helfert","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0045|cit45","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.09.017","article-title":"How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?","volume":"149","author":"Hoffman","year":"2010","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3111\/13696998.2012.670174","article-title":"Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine","volume":"15","author":"Ikenberg","year":"2012","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Jensen TS Baron R Haanp\u00e4\u00e4 M Kalso E Loeser JD Rice AS A new definition of neuropathic pain Pain 2011 152 10 2204 5 10.1016\/j.pain.2011.06.017","DOI":"10.1016\/j.pain.2011.06.017"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"f7339","DOI":"10.1136\/bmj.f7339","article-title":"Drugs for neuropathic pain","volume":"347","author":"Kalso","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000110284","article-title":"Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984","volume":"10","author":"Katusic","year":"1991","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1111\/papr.12143","article-title":"Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?","volume":"14","author":"Kern","year":"2014","journal-title":"Pain Practice"},{"issue":"12","key":"10.1002\/14651858.CD007393.pub4-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1016\/j.pain.2013.08.001","article-title":"Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study","volume":"154","author":"Knolle","year":"2013","journal-title":"Pain"},{"issue":"1-3","key":"10.1002\/14651858.CD007393.pub4-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","article-title":"Incidence of facial pain in the general population","volume":"147","author":"Koopman","year":"2009","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6904-1-3","article-title":"Reporting of adverse drug reactions in randomised controlled trials - a systematic survey","volume":"1","author":"Loke","year":"2001","journal-title":"BMC Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007393.pub4-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD007393.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"R644","DOI":"10.1186\/ar1704","article-title":"Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0060|cit60","first-page":"15","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD007393.pub4-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar2422","article-title":"Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports","volume":"10","author":"Moore","year":"2008","journal-title":"Arthritis Research and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD007393.pub4-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007393.pub4-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub2","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2326-11-4","article-title":"Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data","volume":"11","author":"Moore","year":"2011","journal-title":"BMC Blood Disorders"},{"issue":"12","key":"10.1002\/14651858.CD007393.pub4-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub3","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0072|cit72","first-page":"50","volume-title":"Statistics with Confidence - Confidence Intervals and Statistical Guidelines","author":"Morris","year":"1995"},{"issue":"9","key":"10.1002\/14651858.CD007393.pub4-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.pain.2013.04.044","article-title":"Efficacy of Qutenza\u00ae (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database","volume":"154","author":"Mou","year":"2013","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0074|cit74","unstructured":"National Institute for Health and Care Excellence (NICE) Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013 www.nice.org.uk\/guidance\/cg173"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007393.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1526-4637.2009.00685","article-title":"Patient-centered perspective on treatment outcomes in chronic pain","volume":"11","author":"O'Brien","year":"2010","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0077|cit77","unstructured":"A randomized, controlled, long-term safety study evaluating the effect of repeated applications of QUTENZATM plus standard of care versus standard of care alone in patients with painful diabetic peripheral neuropathy www.astellasclinicalstudyresults.com\/hcp\/study.aspx?ID=75 NCT01478607"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0078|cit78","unstructured":"PaPaS author and referee guidance papas.cochrane.org\/papas-documents"},{"issue":"12","key":"10.1002\/14651858.CD007393.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e14433","DOI":"10.1371\/journal.pone.0014433","article-title":"Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials","volume":"5","author":"Phillips","year":"2010","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0304-3959(94)90086-8","article-title":"Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion","volume":"56","author":"Rappaport","year":"1994","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0081|cit81","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/AJP.0b013e318287a32f","article-title":"NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study","volume":"30","author":"Simpson","year":"2014","journal-title":"Clinical Journal of Pain"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/rheumatology\/kep432","article-title":"Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports","volume":"49","author":"Straube","year":"2010","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2474-12-125","article-title":"Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response","volume":"12","author":"Straube","year":"2011","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0085|cit85","unstructured":"A multicentre, single-arm, open-label study of the repeated administration of QUTENZA TM for the treatment of peripheral neuropathic pain www.astellasclinicalstudyresults.com\/hcp\/study.aspx?ID=81"},{"key":"10.1002\/14651858.CD007393.pub4-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-9","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"Journal of Pain"},{"issue":"18","key":"10.1002\/14651858.CD007393.pub4-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40122-014-0027-1","article-title":"High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know","volume":"3","author":"\u0170\u00e7eyler","year":"2014","journal-title":"Pain and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"Hecke","year":"2014","journal-title":"Pain"},{"issue":"7","key":"10.1002\/14651858.CD007393.pub4-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"A659","DOI":"10.1016\/j.jval.2015.09.2388","article-title":"A systematic literature review and network meta-analysis of capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy","volume":"18","author":"Nooten","year":"2015","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuron.2012.02.008","article-title":"Deconstructing the neuropathic pain phenotype\u00a0to reveal neural mechanisms","volume":"73","author":"Hehn","year":"2012","journal-title":"Neuron"},{"issue":"9859","key":"10.1002\/14651858.CD007393.pub4-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007393.pub4-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010567.pub2","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007393.pub4-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007393.pub2","article-title":"Topical capsaicin for chronic neuropathic pain in adults","author":"Derry","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007393.pub4-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007393.pub3","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7446","key":"10.1002\/14651858.CD007393.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/bmj.38042.506748.EE","article-title":"Systematic review of topical capsaicin for the treatment of chronic pain","volume":"328","author":"Mason","year":"2004","journal-title":"BMJ (Clinical Research Ed)"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007393.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:47:32Z","timestamp":1755852452000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007393.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007393.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}